Tufts Health Care Institute Program on
| |||
September 7 — 8, 2006
Day 1 – September 7, 2006 Welcome & Introductions Responsibilities of the Pharmaceutical Industry What are the legal and ethical responsibilities of a pharmaceutical company to intervene in response to prescription drug abuse Issues in Pre-marketing Risk Assessment Does scheduling reduce risk: a review of the evidence Best practices in evaluating extractability/tampering Surveillance & Related Issues Choosing surveillance systems to meet specific needs Quantitative approaches to differentiating signal from noise: best practices Field studies for signal verification: best practices Interventions Patient and consumer education: best practices How can pharmaceutical companies team up with health care systems to promote appropriate opioid prescribing? Day 2 – September 8, 2006 Interventions Perspectives from the field: what works and what doesn’t in a high-risk community Opioid prescribing: best practices in clinician education Physician guiding systems for opioid prescribing Best Practices in Developing a Risk Management Action Plan
| |||
|
©
2010 Tufts Health Care Institute •
Boston, MA 02111 •
(617) 636-1000 |
|||
The mission of the Tufts Health Care Institute Program on Opioid Risk Management is to address challenges in the development and utilization of opioid analgesics, by engaging a multidisciplinary group of stakeholders focused on optimizing the benefits of opioid for pain management, and minimizing their risks, including abuse and diversion.